-
公开(公告)号：US11111293B2
公开(公告)日：2021-09-07
申请号：US16111659
申请日：2018-08-24
Applicant: NOVARTIS AG
Inventor： Michael Otto Bardroff , Barbara Brannetti , Emma Michelle Campbell , Beate Diefenbach-Streiber , Adina Eberth , Christian Carsten Silverster Kunz , Sylwia Marshall , Jean-Michel Rene Rondeau , Jean-Marc Alfred Schlaeppi , Gino Anselmus Van Heeke
Abstract: Interleukin-18 (IL-18) participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.
-
公开(公告)号：US20180207273A1
公开(公告)日：2018-07-26
申请号：US15747326
申请日：2016-07-28
Applicant: Glenn Dranoff , Catherine Anne Sabatos-Peyton , Barbara Brannetti , Alan S. Harris , Thomas Huber , Thomas Pietzonka , Jennifer Marie Mataraza , Walter A. Blattler , Daniel J. Hicklin , Maximiliano Vasquez , Rosemarie H. DeKruyff , Dale T. Umetsu , Gordon James Freeman , Tiancen Hu , John A. Taraszka , Fangmin Xu , Novartis AG , DANA-FARBER CANCER INSTITUTE, INC. , Children's Medical Center Corporation
Inventor： Glenn Dranoff , Catherine Anne Sabatos-Peyton , Barbara Brannetti , Alan S. Harris , Thomas Huber , Thomas Pietzonka , Jennifer Marie Mataraza , Walter A. Blattler , Daniel J. Hicklin , Maximiliano Vasquez , Rosemarie H. DeKruyff , Dale T. Umetsu , Gordon James Freeman , Tiancen Hu , John A. Taraszka , Fangmin Xu
IPC: A61K39/395 , A61K45/06 , A61P35/00
CPC classification number: A61K39/39566 , A61K39/00 , A61K39/3955 , A61K45/06 , A61K2039/507 , A61P35/00 , C07K16/2803 , C07K2299/00 , C07K2317/24 , C07K2317/34 , C07K2317/76 , C07K2317/94 , A61K2300/00
Abstract: Combination therapies comprising antibody molecules that specifically bind to TIM-3 are disclosed. The combination therapies can be used to treat or prevent cancerous or infectious conditions and disorders.
-
公开(公告)号：US20170190777A1
公开(公告)日：2017-07-06
申请号：US15462585
申请日：2017-03-17
Inventor： Catherine Anne Sabatos-Peyton , Barbara Brannetti , Alan S. Harris , Thomas Huber , Thomas Pietzonka , Jennifer Marie Mataraza , Walter A. Blattler , Daniel J. Hicklin , Maximiliano Vasquez , Rosemarie H. DeKruyff , Dale T. Umetsu , Gordon James Freeman , Tiancen Hu , John A. Taraszka , Fangmin Xu
IPC: C07K16/28
CPC classification number: C07K16/2803 , A61K39/3955 , A61K39/39558 , A61K45/06 , C07K2299/00 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2317/94 , G01N33/6893
Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.
-
公开(公告)号：US11872249B2
公开(公告)日：2024-01-16
申请号：US17246351
申请日：2021-04-30
Inventor： Barbara Brannetti , Jennifer Brogdon , Boris Engels , Brian Walter Granda , Lu Huang , Ming Lei , Na Li , Jimin Zhang , Carla Patricia Pinto Guimaraes , Saar Gill , Marco Ruella , Regina M. Young
CPC classification number: A61K35/17 , A61K38/1774 , A61P35/00 , C07K16/2803 , C07K16/2887 , C07K16/2896 , C12N15/85 , A61K2039/505 , C07K2317/24 , C07K2317/31 , C07K2317/622 , C07K2319/03 , C07K2319/33
Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
-
5.发明公开公开(公告)号：US20230374105A1
公开(公告)日：2023-11-23
申请号：US18339565
申请日：2023-06-22
Inventor： Hans Bitter , Jennifer Mary Bordeaux , Barbara Brannetti , Jennifer Brogdon , Naveen Kumar Dakappagari , Saar Gill , Steven Highfill , Lu Huang , Carl H. June , Ju Young Kim , Ming Lei , Na Li , Andreas Loew , Elena Orlando , Marco Ruella , Thai Tran , Jimin Zhang , Li Zhou
IPC: C07K14/705 , C07K14/725 , C07K16/28 , A61K45/06 , A61K39/00
CPC classification number: C07K14/70596 , C07K14/7051 , C07K16/2803 , C07K16/2866 , A61K45/06 , A61K39/001112 , A61K39/001113 , A61K39/001124 , C07K2317/24 , C07K2317/622 , C07K2319/00 , A61K2039/5156 , A61K2039/5158 , A61K2039/70 , A61K38/00
Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.
-
Patent Agency Ranking
公开(公告)号：US20220195010A1
公开(公告)日：2022-06-23
申请号：US17464528
申请日：2021-09-01
Inventor： Hans Bitter , Jennifer Mary Bordeaux , Barbara Brannetti , Jennifer Brogdon , Naveen Kumar Dakappagari , Saar Gill , Steven Highfill , Lu Huang , Carl H. June , Ju Young Kim , Ming Lei , Na Li , Andreas Loew , Elena Orlando , Marco Ruella , Thai Tran , Jimin Zhang , Li Zhou
IPC: C07K14/705 , C07K14/725 , C07K16/28 , A61K45/06 , A61K39/00
Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.
-
公开(公告)号：US10981990B2
公开(公告)日：2021-04-20
申请号：US16841029
申请日：2020-04-06
Applicant: Novartis AG , DANA-FARBER CANCER INSTITUTE, INC. , The Children's Medical Center Corporation
Inventor： Catherine Anne Sabatos-Peyton , Barbara Brannetti , Alan S. Harris , Thomas Huber , Thomas Pietzonka , Jennifer Marie Mataraza , Walter A. Blattler , Daniel J. Hicklin , Maximiliano Vasquez , Rosemarie H. DeKruyff , Dale T. Umetsu , Gordon James Freeman , Tiancen Hu , John A. Taraszka , Fangmin Xu
IPC: A61K39/395 , C07K16/28 , G01N33/574 , A61K45/06 , G01N33/68
Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.
-
公开(公告)号：US20170198041A1
公开(公告)日：2017-07-13
申请号：US15432819
申请日：2017-02-14
Inventor： Catherine Anne Sabatos-Peyton , Barbara Brannetti , Alan S. Harris , Thomas Huber , Thomas Pietzonka , Jennifer Marie Mataraza , Walter A. Blattler , Daniel J. Hicklin , Maximiliano Vasquez , Rosemarie H. DeKruyff , Dale T. Umetsu , Gordon James Freeman , Tiancen Hu , John A. Taraszka , Fangmin Xu
IPC: C07K16/28 , A61K45/06 , G01N33/68 , A61K39/395
Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.
-
9.再颁专利公开(公告)号：USRE49847E1
公开(公告)日：2024-02-27
申请号：US17569389
申请日：2022-01-05
Inventor： Barbara Brannetti , Jennifer Brogdon , Boris Engels , Brian Granda , Lu Huang , Ming Lei , Na Li , Jimin Zhang , Carla Guimaraes , Saar Gill , Marco Ruella , Regina M. Young
CPC classification number: A61K35/17 , A61K38/1774 , A61P35/00 , C07K16/2803 , C07K16/2887 , C07K16/2896 , C12N15/85 , A61K2039/505 , C07K2317/24 , C07K2317/31 , C07K2317/622 , C07K2319/03 , C07K2319/33
Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
-
10.发明申请公开(公告)号：US20210246200A1
公开(公告)日：2021-08-12
申请号：US17124930
申请日：2020-12-17
Applicant: Novartis AG , Universität Zürich
Inventor： Natalia Arenas-Ramirez , Iwan Beuvink , Onur Boyman , Barbara Brannetti , Andreas Katopodis , Simone Popp , Catherine Regnier , Chao Zou
Abstract: The present invention relates to antibodies binding to human interleukin-2 (hIL-2). The invention more specifically relates to humanized antibodies specifically binding a particular epitope of hIL-2 and, when bound to this epitope, displaying a unique capability of inhibiting binding of hIL-2 to CD25.
-
-
-
-
-
-
-
-
-
Search Results
32
records
(took 0.031 seconds)
